JP2021505537A5 - - Google Patents

Info

Publication number

JP2021505537A5

JP2021505537A5 JP2020527818A JP2020527818A JP2021505537A5 JP 2021505537 A5 JP2021505537 A5 JP 2021505537A5 JP 2020527818 A JP2020527818 A JP 2020527818A JP 2020527818 A JP2020527818 A JP 2020527818A JP 2021505537 A5 JP2021505537 A5 JP 2021505537A5

Authority

JP

Japan

Prior art keywords

compound according

compound

alkyl

pharmaceutically acceptable

substituted

Prior art date

2018-12-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims 32
• 150000003839 salts Chemical class 0.000 claims 15
• 125000004450 alkenylene group Chemical group 0.000 claims 9
• 125000000217 alkyl group Chemical group 0.000 claims 9
• 125000002947 alkylene group Chemical group 0.000 claims 9
• CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 9
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
• 239000012453 solvate Substances 0.000 claims 7
• 229910052736 halogen Inorganic materials 0.000 claims 6
• 150000002367 halogens Chemical class 0.000 claims 6
• 125000003003 spiro group Chemical group 0.000 claims 6
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
• 125000000623 heterocyclic group Chemical group 0.000 claims 5
• 229910052739 hydrogen Inorganic materials 0.000 claims 5
• 239000001257 hydrogen Substances 0.000 claims 5
• 125000003342 alkenyl group Chemical group 0.000 claims 4
• 125000004429 atom Chemical group 0.000 claims 4
• 229960003624 creatine Drugs 0.000 claims 4
• 239000006046 creatine Substances 0.000 claims 4
• 125000000753 cycloalkyl group Chemical group 0.000 claims 4
• 201000010099 disease Diseases 0.000 claims 4
• 230000007812 deficiency Effects 0.000 claims 3
• 208000035475 disorder Diseases 0.000 claims 3
• 125000005842 heteroatom Chemical group 0.000 claims 3
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
• 102100023153 Sodium- and chloride-dependent creatine transporter 1 Human genes 0.000 claims 2
• 108700005875 X-linked Creatine deficiency Proteins 0.000 claims 2
• 208000034091 X-linked creatine transporter deficiency Diseases 0.000 claims 2
• 229910052799 carbon Inorganic materials 0.000 claims 2
• 108010007169 creatine transporter Proteins 0.000 claims 2
• 201000002997 creatine transporter deficiency Diseases 0.000 claims 2
• 235000019253 formic acid Nutrition 0.000 claims 2
• 229910003002 lithium salt Inorganic materials 0.000 claims 2
• 159000000002 lithium salts Chemical class 0.000 claims 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
• 208000024172 Cardiovascular disease Diseases 0.000 claims 1
• 102000004420 Creatine Kinase Human genes 0.000 claims 1
• 108010042126 Creatine kinase Proteins 0.000 claims 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
• 208000028782 Hereditary disease Diseases 0.000 claims 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
• 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
• 208000024556 Mendelian disease Diseases 0.000 claims 1
• 206010049565 Muscle fatigue Diseases 0.000 claims 1
• 108091000080 Phosphotransferase Proteins 0.000 claims 1
• 208000028017 Psychotic disease Diseases 0.000 claims 1
• 206010063837 Reperfusion injury Diseases 0.000 claims 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
• 125000003118 aryl group Chemical group 0.000 claims 1
• 230000015572 biosynthetic process Effects 0.000 claims 1
• 238000009833 condensation Methods 0.000 claims 1
• 230000005494 condensation Effects 0.000 claims 1
• 208000029487 creatine biosynthetic process disease Diseases 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 125000001072 heteroaryl group Chemical group 0.000 claims 1
• 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
• 230000000302 ischemic effect Effects 0.000 claims 1
• 201000006417 multiple sclerosis Diseases 0.000 claims 1
• 230000004770 neurodegeneration Effects 0.000 claims 1
• 208000015122 neurodegenerative disease Diseases 0.000 claims 1
• 230000036542 oxidative stress Effects 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 102000020233 phosphotransferase Human genes 0.000 claims 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
• 239000011734 sodium Substances 0.000 claims 1
• 159000000000 sodium salts Chemical class 0.000 claims 1
• 239000002904 solvent Substances 0.000 claims 1
• 238000003786 synthesis reaction Methods 0.000 claims 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 1
• 0 *=C(*CC(OCCCCCCCCCC1)=O)NC1=O Chemical compound *=C(*CC(OCCCCCCCCCC1)=O)NC1=O 0.000 description 10
• OIUBAEJAAVIFBZ-UHFFFAOYSA-N CC(CCCCCCCCCCC(NC(N(C)C1)=N)=O)OC1=O Chemical compound CC(CCCCCCCCCCC(NC(N(C)C1)=N)=O)OC1=O OIUBAEJAAVIFBZ-UHFFFAOYSA-N 0.000 description 1
• OIUBAEJAAVIFBZ-CQSZACIVSA-N C[C@H](CCCCCCCCCCC(NC(N(C)C1)=N)=O)OC1=O Chemical compound C[C@H](CCCCCCCCCCC(NC(N(C)C1)=N)=O)OC1=O OIUBAEJAAVIFBZ-CQSZACIVSA-N 0.000 description 1